The COVID-19 PHARMACOME: Rational Selection of Drug Repurposing Candidates from Multimodal Knowledge Harmonization
暂无分享,去创建一个
Martin Hofmann-Apitius | Andrea Zaliani | Reagon Karki | Alpha Tom Kodamullil | Roland Eils | Daniel Domingo-Fernández | Bruce Schultz | Christian Ebeling | Jeanette Reinshagen | Denisa Bojkova | Vanessa Lage-Rupprecht | Sören Lukassen | Yojana Gadiya | Neal G. Ravindra | Sayoni Das | Shounak Baksi | Manuel Lentzen | Mark Strivens | Tamara Raschka | Jindrich Cinatl | Lauren Nicole DeLong | Phil Gribbon | Gerd Geisslinger | Sandra Ciesek | David van Dijk | Steve Gardner | Holger Fröhlich | Manuel Peitsch | Marc Jacobs | Julia Hoeng | Carsten Claussen | M. Peitsch | R. Eils | H. Fröhlich | M. Hofmann-Apitius | M. Strivens | C. Ebeling | S. Ciesek | D. van Dijk | J. Hoeng | J. Cinatl | N. Ravindra | S. Lukassen | D. Bojkova | G. Geisslinger | Sayoni Das | P. Gribbon | A. Zaliani | V. Lage-Rupprecht | Shounak Baksi | Carsten Claussen | Jeanette Reinshagen | Tamara Raschka | Steve Gardner | Yojana Gadiya | L. Delong | Reagon Karki | Bruce Schultz | Manuel Lentzen | M. Jacobs | A. Kodamullil | D. Domingo-Fernándéz | M. Lentzen | Christian Ebeling | David van Dijk
[1] Wei Cao,et al. COVID-19: towards understanding of pathogenesis , 2020, Cell Research.
[2] Martin Hofmann-Apitius,et al. ComPath: an ecosystem for exploring, analyzing, and curating mappings across pathway databases , 2018, npj Systems Biology and Applications.
[3] S. Jois,et al. The anti‐HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV‐2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID‐19 infections , 2020, bioRxiv.
[4] Dominic Winter,et al. Comprehensive draft of the mouse embryonic fibroblast lysosomal proteome by mass spectrometry based proteomics , 2020, Scientific Data.
[5] T. Ashburn,et al. Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.
[6] Roland Eils,et al. COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis , 2020, Nature Biotechnology.
[7] Martin Hofmann-Apitius,et al. Computable cause-and-effect models of healthy and Alzheimer's disease states and their mechanistic differential analysis , 2015, Alzheimer's & Dementia.
[8] Y. Benjamini. Discovering the false discovery rate , 2010 .
[9] Jindrich Cinatl,et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus , 2004, Biochemical and Biophysical Research Communications.
[10] R. Schwartz,et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.
[11] Benjamin J. Polacco,et al. A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing , 2020, Nature.
[12] Farhana Musarrat,et al. The anti‐HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV‐2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID‐19 infections , 2020, Journal of medical virology.
[13] C. Buckee,et al. Wrong but Useful - What Covid-19 Epidemiologic Models Can and Cannot Tell Us. , 2020, The New England journal of medicine.
[14] Torsten Schwede,et al. A Comprehensive Mapping of the Druggable Cavities within the SARS-CoV-2 Therapeutically Relevant Proteins by Combining Pocket and Docking Searches as Implemented in Pockets 2.0 , 2020, International journal of molecular sciences.
[15] Jonas Ardö,et al. The FLUXNET2015 dataset and the ONEFlux processing pipeline for eddy covariance data , 2020, Scientific Data.
[16] A. Barabasi,et al. Network medicine framework for identifying drug-repurposing opportunities for COVID-19 , 2020, Proceedings of the National Academy of Sciences.
[17] P. Sanseau,et al. Drug repurposing: progress, challenges and recommendations , 2018, Nature Reviews Drug Discovery.
[18] M. Tay,et al. The trinity of COVID-19: immunity, inflammation and intervention , 2020, Nature Reviews Immunology.
[19] Andrew D. Rouillard,et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..
[20] S. Ciesek,et al. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets , 2020, Nature.
[21] Denisa Bojkova,et al. Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China , 2020, The New England journal of medicine.
[22] M. Lipsitch,et al. Defining the Epidemiology of Covid-19 - Studies Needed. , 2020, The New England journal of medicine.
[23] John S. Brownstein,et al. Epidemiological data from the COVID-19 outbreak, real-time case information , 2020, Scientific Data.
[24] Martin Hofmann-Apitius,et al. PathMe: merging and exploring mechanistic pathway knowledge , 2018, BMC Bioinformatics.
[25] Lin Cheng,et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 , 2020, Nature Medicine.
[26] S. Ciesek,et al. Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells using a large scale drug repurposing collection , 2020 .
[27] E. Barillot,et al. Atlas of Cancer Signalling Network: a systems biology resource for integrative analysis of cancer data with Google Maps , 2015, Oncogenesis.
[28] Andrew I. Su,et al. The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis , 2018, Proceedings of the National Academy of Sciences.
[29] Hiroaki Kitano,et al. COVID-19 Disease Map, building a computational repository of SARS-CoV-2 virus-host interaction mechanisms , 2020, Scientific Data.
[30] T. Pawson,et al. Network medicine , 2008, FEBS letters.
[31] Samik Ghosh,et al. Integrating Pathways of Parkinson's Disease in a Molecular Interaction Map , 2013, Molecular Neurobiology.
[32] Samik Ghosh,et al. A comprehensive map of the influenza A virus replication cycle , 2013, BMC Systems Biology.
[33] Ted Slater,et al. Recent advances in modeling languages for pathway maps and computable biological networks. , 2014, Drug discovery today.
[34] Sam Michael,et al. Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro , 2020, bioRxiv.
[35] Martin Hofmann-Apitius,et al. COVID-19 Knowledge Graph: a computable, multi-modal, cause-and-effect knowledge model of COVID-19 pathophysiology , 2020, bioRxiv.
[36] Martin Hofmann-Apitius,et al. COVID-19 Knowledge Graph: a computable, multi-modal, cause-and-effect knowledge model of COVID-19 pathophysiology , 2020, bioRxiv.
[37] Joel R. Huff,et al. HIV Protease Inhibitor , 1992 .
[38] Ruth R. Montgomery,et al. Single-cell longitudinal analysis of SARS-CoV-2 infection in human airway epithelium , 2020, bioRxiv.
[39] Ruth R. Montgomery,et al. Single-cell longitudinal analysis of SARS-CoV-2 infection in human bronchial epithelial cells , 2020 .